Heart Failure Clinical Trials in Louisville, Kentucky

12 studies are recruiting for heart failure in Louisville, Kentucky right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

    Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screenin…

    Stage
    Phase 3
    Ages
    40 and older
    Site
    Research Site, Louisville, Kentucky
    Locations
    957 in total
    Run by
    AstraZeneca
  2. A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

    Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Louisville, KY Investigative Site 10006, Louisville, Kentucky
    Locations
    356 in total
    Run by
    Colorado Prevention Center
  3. A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

    Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    CON-10086, Louisville, Kentucky, Louisville, Kentucky
    Locations
    140 in total
    Run by
    Colorado Prevention Center
  4. Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

    The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.

    Stage
    Not phased
    Ages
    18 to 100
    Site
    University of Louisville, Louisville, Kentucky
    Locations
    47 in total
    Run by
    BrioHealth Solutions, Inc.
  5. Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK…

    Stage
    Not phased
    Ages
    0 to 20
    Site
    University of Louisville Norton Childrens Hospital, Louisville, Kentucky
    Locations
    52 in total
    Run by
    Duke University
  6. A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

    This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empa…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Norton Heart Specialists, Louisville, Kentucky
    Locations
    652 in total
    Run by
    Boehringer Ingelheim
  7. Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

    The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

    Stage
    Not phased
    Ages
    Any age
    Site
    Research site, Louisville, Kentucky
    Locations
    333 in total
    Run by
    Medtronic
  8. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

    This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    UofL Health Care Outpatient, Louisville, Kentucky
    Locations
    838 in total
    Run by
    Novo Nordisk A/S
  9. A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

    This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by cha…

    Stage
    Phase 2
    Ages
    40 to 84
    Site
    UofL Health Care Outpatient, Louisville, Kentucky
    Locations
    117 in total
    Run by
    Novo Nordisk A/S
  10. A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

    Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).

    Stage
    Phase 3
    Ages
    18 and older
    Site
    FIN-10086, Louisville, KY, Louisville, Kentucky
    Locations
    176 in total
    Run by
    Colorado Prevention Center
  11. Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

    The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Norton Hospital, Louisville, Kentucky
    Locations
    68 in total
    Run by
    Abbott Medical Devices
  12. Left vs Left Randomized Clinical Trial

    The investigators aim to prospectively test the comparative effectiveness of His or Left bundle branch pacing in relation to patient centered outcomes (quality of life, physical activity, heart failure hospitalization, mortality) and comparative safety in relation to device-related complications an…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Baptist Health Louisville, Louisville, Kentucky
    Locations
    71 in total
    Run by
    Baylor College of Medicine

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.